SubscribeLogin
Published

AHA 2024: Five-year Amulet IDE data show similar outcomes with Amplatzer and Watchman devices - Cardiovascular News

Summary by Cardiovascular News
Dhanunjaya Lakkireddy Latest data from the Amulet investigational device exemption (IDE) trial, comparing the Amplatzer Amulet (Abbott) left atrial appendage occluder (LAAO) to the first-generation Watchman 2.5 (Boston Scientific) in patients with non-valvular atrial fibrillation (AF) at increased risk of stroke, demonstrate similar clinical outcomes with the two devices out to five years. Results of the trial were presented at the American Hear…
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Chicago, ILChicago, IL
Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal